Eli Lilly secures exclusive rights to chronic pain treatment

American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly to acquire Dermira for $1.1 billion

16 January 2020 Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.

Americas

Eli Lilly licenses AI tech for preclinical development

6 June 2019 San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.

Americas

Eli Lilly releases generic insulin injection

23 May 2019 Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.